fda warning letter glp-1 october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Beyond the Headlines: FDA Warning

Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis

The analysis found semaglutide drugs like Ozempic increased the risk of DVT by 266%

Employers should consider requiring documented diagnoses, evidence-based prior authorization, and stepped therapy, plus lifestyle programs before approving GLP-1s for weight loss to curb long-term spend

Gabriel Chiu can help you navigate your insurance and cost concerns

Type 2 diabetes typically worsens over time without intervention, and stopping effective medication often results in deteriorating glycaemic control

Lost Wages: Compensation for time off work due to Wegovy effects or treatments